RESONATE-2: 7-year follow-up data

Media Center
‌
‌
Prof. Paolo Ghia discusses the latest 7-year follow-up IMBRUVICA® data in 1L CLL RESONATE-2 reinforces confidence in long-term survival with IMBRUVICA®, including those with high-risk genetic features[1]
© Janssen Pharmaceutica NV 2024. This site is published by Janssen Pharmaceutica NV which is solely responsible for its content. This site is intended for use by Healthcare Professionals in Europe, Middle East and Africa.
Privacy PolicyCookie PolicyLegal Notice
Cookie Settings
Logo